Navigation Links
Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL)
Date:12/8/2008

13; E: hth@genmab.com

Cautionary statement regarding forward-looking statements for GSK

Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under 'Risk Factors' in the 'Business Review' in the company's Annual Report on Form 20-F for 2007.

Registered in England & Wales:

No. 3888792

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS

Forward looking statement for Genmab

This press release contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsole
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
4. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
5. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
8. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
9. New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies
10. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
11. Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014 According to ... by Extraction type (SFE, Cold Pressed, Organic Solvent, & ... Pharmaceutical, Food Supplements, Fragrance, & Others) - Global Trends ... and segments the Amaranth Seed Oil Market with ... in terms of value. The Amaranth Seed Oil ...
(Date:8/29/2014)... 2014  United Therapeutics Corporation (NASDAQ: UTHR ... the District of New Jersey ... against Sandoz, Inc. regarding United Therapeutics, Remodulin ® ... that U.S. Patent No. 6,765,117 is both valid and ... its generic product until the expiration of that patent ...
(Date:8/29/2014)... 29, 2014 Diseases largely eradicated in ... are returning. Measles was declared eliminated in 2000, yet ... of August 15—the highest incidence in 20 years. In ... declared whooping cough a problem of "epidemic proportions." ... and dying from these preventable diseases—in part because some ...
Breaking Medicine Technology:Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4District Court Decision Received In Remodulin Patent Case 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3
... Israel--(BUSINESS WIRE)--Jun 14, 2007 - Can-Fite,BioPharma (TASE:CFBI), a ... Exchange, proceeds with the development of its,third drug ... is currently,in clinical trials and CF102, which is ... the EUALR annual congress of,rheumatology in-vitro and in ...
... of SLE,disease at 52 Weeks and demonstrated ... ROCKVILLE, Md., June 14, 2007 /PRNewswire-FirstCall/ -- ... of Phase 2,trial data demonstrating that LymphoStat-B(R) ... was well tolerated and improved quality of ...
Cached Medicine Technology:Can-Fite Proceeds with Development of Third Drug; Progress in,Development of CF502 Will Be Presented at the Annual European,Congress of Rheumatology 2Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 2Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 3Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 4Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 5Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 6Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 7Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 8
(Date:9/1/2014)... known as marijuana is broadly believed to ... (MGH) investigators found that 40 percent of cannabis-using ... reported experiencing symptoms of withdrawal, which are considered ... reporting withdrawal were more likely to meet criteria ... although the presence or absence of withdrawal did ...
(Date:9/1/2014)... Building on the success of the ... and Breathing Academy (ASBA) has officially announced its ... Professionals. The event will be taking place at the ... 11th. This years’ event promises to be yet another ... , In recent years, Pro Player Health Alliance ...
(Date:9/1/2014)... HealthDay Reporter SATURDAY, Aug. 30, ... experimental drug was more effective than standard treatment at ... According to the study authors, the trial was stopped ... drug, dubbed LCZ696. In the trial, 26.5 ... either died or were hospitalized due to heart failure, ...
(Date:9/1/2014)... Albany, New York (PRWEB) September 01, 2014 ... specially-fitted room in a hospital for performing surgical operations. ... such as operating tables, surgical booms, operating room lights, ... rooms. According to a report by Transparency Market Research, ... market is expected to reach USD 4.5 billion by ...
(Date:9/1/2014)... 1 September 2014: Daily fruit consumption cuts the risk ... to research presented at ESC Congress today by Dr ... seven year follow-up study of nearly 0.5 million people ... fruit people ate, the more their risk of CVD ... disease (IHD) and stroke, is the leading cause of ...
Breaking Medicine News(10 mins):Health News:Cannabis withdrawal symptoms common among adolescents treated for substance use disorder 2Health News:Cannabis withdrawal symptoms common among adolescents treated for substance use disorder 3Health News:Pro Player Health Alliance Confirms Big Name Speakers at 2015 American Sleep and Breathing Academy Conference 2Health News:Pro Player Health Alliance Confirms Big Name Speakers at 2015 American Sleep and Breathing Academy Conference 3Health News:Pro Player Health Alliance Confirms Big Name Speakers at 2015 American Sleep and Breathing Academy Conference 4Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 2Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 3Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 2Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 3Health News:Fruit consumption cuts CVD risk by up to 40 percent 2Health News:Fruit consumption cuts CVD risk by up to 40 percent 3
... DARIEN, Ill., June 17 Healthation CEO Scott ... Vice President of,Business Development today. Mr. Hebert was ... experience in sales of complex solutions in the ... the sales and,marketing organization and growing market share ...
... PartsSource, the nation,s leading,supplier of replacement medical ... straight "World Class Customer Service" award for Northern,Ohio. ... Promise and,its ability to consistently meet or exceed ... by Smart Business magazine, which further,honored PartsSource,s President ...
... NORTH HOLLYWOOD, Calif., June 17 IPC The,Hospitalist ... national hospitalist,physician group practice, today announced that it ... and Exchange Commission in connection,with a proposed offering ... shares to be registered include 3,889,769 shares owned ...
... extract reduces plaque formation and resulting cognitive impairment in ... The study appears in the June 18 issue of ... study author Giulio Pasinetti, MD, PhD, of Mount Sinai ... seed extract prevents amyloid beta accumulation in cells, suggesting ...
... researchers at Washington University School of Medicine in St. ... the risk of metabolic syndrome, a group of factors ... found appeared to protect against the condition. , People ... following symptoms: abdominal obesity, high blood triglyceride levels, lower ...
... and stress-reduction spur healthy alterations in DNA, study finds, ... not fully control your destiny when it comes to ... with prostate cancer. , New research suggests that stringent ... can change the expression of hundreds of genes. ...
Cached Medicine News:Health News:IPC The Hospitalist Company, Inc. Files Registration Statement for Proposed Offering 2Health News:IPC The Hospitalist Company, Inc. Files Registration Statement for Proposed Offering 3Health News:Study indicates grape seed extract may reduce cognitive decline associated with Alzheimer's disease 2Health News:Study indicates grape seed extract may reduce cognitive decline associated with Alzheimer's disease 3Health News:Gene variants linked to metabolic syndrome and HDL cholesterol levels 2Health News:Gene variants linked to metabolic syndrome and HDL cholesterol levels 3Health News:Lifestyle Changes Affect Cancer Genes 2Health News:Lifestyle Changes Affect Cancer Genes 3
Shepard tying forceps, round curved platform 8 mm, 8.5 cm....
Girard straight tying forceps made of titanium has straight shafts with 6 mm tying platforms, width of shafts 0,25 mm, TCI platforms, round handle, diam. 6 mm, overall length 105 mm....
McPherson curved tying forceps made of titanium has curved shafts with 8 mm tying platforms, width of shafts 0,25 mm, TCI platforms, flat handle, width 6 mm, overall length 85 mm....
McPherson straight tying forceps made of titanium, straight shafts with 4 mm tying platforms, width of shafts 0,25 mm, TCI platforms, flat handle, width 6 mm, overall length 87 mm....
Medicine Products: